Biotech and Pharmaceuticals Pharmaceuticals

  • *Indivior says launches generic version of Suboxone in U.S. market. Feb 20- British drugmaker Indivior Plc said on Wednesday it had launched a copycat version of its blockbuster opioid addiction drug Suboxone in the United States, just one day after a court decision cleared the way for its rivals to market generic versions of it. The U.S. Supreme Court ruling...

  • WASHINGTON, Feb 19- The U.S. government has reached a settlement with Teva Pharmaceuticals Industries Ltd over charges that its agreements with rivals impeded consumer access to lower-priced generic drugs. In Congress, Senator Amy Klobuchar, a Democrat now running for president, and Senator Chuck Grassley, the Republican chair of the Judiciary Committee,...

  • WASHINGTON, Feb 19- The U.S. government has reached a settlement with Teva Pharmaceuticals Industries Ltd over charges that its agreements with rivals impeded consumer access to lower-priced generic drugs. The Federal Trade Commission on Tuesday said it had settled three reverse payment fights with units of Teva, which will be prohibited from making any...

  • Feb 19- Billionaire hedge fund manager David Tepper stepped up pressure on Allergan Plc, saying on Tuesday the drugmaker should consider selling itself if management is unable to turn around recent lagging performance. Tepper's hedge fund Appaloosa LP wrote to Allergan's board, just hours after the Botox maker announced it had added a former industry...

  • Feb 19- Billionaire hedge fund manager David Tepper stepped up pressure on Allergan Plc, saying on Tuesday the drugmaker should consider selling itself if management is unable to turn around recent lagging performance. Tepper's hedge fund Appaloosa LP wrote to Allergan's board, just hours after the Botox maker announced it added a former industry executive...

  • Feb 19- Billionaire hedge fund manager David Tepper stepped up pressure on Allergan Plc and said on Tuesday the drugmaker should consider selling itself if management is unable to turn around recent lagging performance. Tepper's hedge fund Appaloosa LP wrote to Allergan's board on Tuesday, just hours after the Botox maker announced it added a former...

  • WASHINGTON, Feb 19- The U.S. Supreme Court on Tuesday rejected Maryland's bid to revive a law aimed at preventing price gouging by pharmaceutical companies, dealing a setback to the power of states to rein in prescription drug costs. The justices declined to take up Maryland's appeal of a 2018 federal appeals court ruling that struck down the state's law, That...

  • TEL AVIV, Feb 19- Teva Pharmaceutical Industries expects its generic version of Mylan's EpiPen to claim about 25 percent of the U.S. market by the end of the year, CEO Kare Schultz said on Tuesday, as the company closes in on a return to growth in 2020.. Wall Street has viewed the EpiPen rival as a welcome profit-booster for Teva as it contends with declining U.S....

  • TEL AVIV, Feb 19- Teva Pharmaceutical Industries expects its generic version of Mylan's EpiPen to have about 25 percent of the U.S. market by the end of 2019, Chief Executive Kare Schultz said on Tuesday. Israel- based Teva, the world's largest generic drugmaker, is already selling its product for adults and plans to start supply of a junior version for young...

  • *Blackmores says it is reviewing its operations in China. SYDNEY, Feb 19- Australian vitamin maker Blackmores Ltd cautioned that weak sales in China, its biggest export market, will drag on its net profit in second half of the year, driving down its shares the most since the company listed three decades ago. Blackmores said it was reviewing its operations in China,...

  • *Drugmakers warn they will avoid Japan if price cuts excessive. TOKYO, Feb 19- Japanese doctor Yasushi Goto remembers prescribing the cancer drug Opdivo to an octogenarian and wondering whether taxpayers might object to helping fund treatment, which at the time cost hundreds of thousands of dollars, for patients in their twilight years. Japan, confronted with...

  • Johnson & Johnson CEO on Apple Watch collaboration: 'Ultimately, we're going to save lives'

    Jim Cramer sits down with Johnson & Johnson Chairman and CEO Alex Gorsky, who speaks to his company's partnership with Apple, deal to buy Auris Health and more.

  • JNJ CEO on Apple collaboration: 'Ultimately, we're going to save lives'

    Jim Cramer sits down with Johnson & Johnson Chairman and CEO Alex Gorsky, who speaks to his company's partnership with Apple, deal to buy Auris Health and more.

  • Alex Gorsky, CEO of Johnson & Johnson

    Jim Cramer sits down with Johnson & Johnson Chairman and CEO Alex Gorsky, who speaks to his company's partnership with Apple, deal to buy Auris Health and more.

  • Canopy Growth operations in Smiths Falls, Ontario.

    Cannabis producer Canopy Growth was set to rally Friday after it reported third-quarter revenue rose 282 percent over the last year.

  • Viagra pill

    Despite competition from other drugmakers, Pfizer has been able to maintain a significant share in the erectile dysfunction market thanks in part to launching its own generic version of the blue, diamond-shaped pill.

  • Feb 14- British drugmaker AstraZeneca Plc beat expectations for product sales in the fourth quarter and forecast a second consecutive year of growth, driven by gains in emerging markets including China and demand for its new cancer medicines. The company was also the latest pharma major to say that it had made extensive preparations for Brexit, adding it...

  • Feb 13- British pharmaceutical firm Clinigen Group Plc said on Wednesday it acquired the U.S. rights to Swiss drugmaker Novartis AG's skin and lung cancer drug Proleukin for a total of $210 million, including some future payments.

  • Feb 12- Generic competitors to British drugmaker Indivior Plc's blockbuster opioid addiction treatment are on course to launch sales next week after the firm's attempt to stay a U.S. The company said on Tuesday it would file a repeat motion to the Supreme Court, after having said last week that it faces rapid losses in market share "in the immediate future" to...

  • NEW DELHI, Feb 11- German drugmaker Bayer AG's Monsanto unit has won proceedings against Indian seed maker Nuziveedu Seeds Ltd in a royalty dispute, lawyers familiar with the matter said. Mahyco Monsanto Biotech, a joint venture between Missouri- based Monsanto and India's Maharashtra Hybrid Seeds Co, "has received a favourable award from the arbitration panel...